周五盘中，中国抗体-B（03681）股价大跌5.64%，引发市场关注。这一显著跌幅似乎与公司高层变动有关。
根据公司公告，中国抗体-B于6月12日收到执行董事王善春先生的辞呈。王善春先生辞去公司执行董事及集团若干附属公司的董事职务，自2025年6月9日起生效。辞任原因据称是为了投入更多时间处理个人事务。值得注意的是，王善春先生在辞任后将不再担任集团内任何职务。
这一突如其来的人事变动可能引发了投资者对公司未来发展的担忧，导致股价下跌。市场将密切关注中国抗体-B后续的人事安排及其对公司经营的潜在影响。目前，公司尚未就此次高管变动对未来发展的影响发表进一步声明。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.